To evaluate the synergistic therapeutic effect of FUdR and Dox, the targeted uptake of Dox@affi-F/AuNPs and their selective inhibitory activity on HER2+ breast cancer cells were investigated. This evidence concerns the gene ERBB2 and breast carcinoma.